Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2474104,Initial apparent half-lives,"Initial apparent half-lives (8-16 h), mean trough concentrations (5-19 ng/ml), and absolute accumulation all increased with worsening renal function, and renal clearance of ramiprilat was significantly correlated with creatinine clearance.",Steady-state kinetics of ramipril in renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2474104/),h,8-16,3454,DB00178,Ramipril
,2474104,trough concentrations,"Initial apparent half-lives (8-16 h), mean trough concentrations (5-19 ng/ml), and absolute accumulation all increased with worsening renal function, and renal clearance of ramiprilat was significantly correlated with creatinine clearance.",Steady-state kinetics of ramipril in renal failure. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2474104/),[ng] / [ml],5-19,3455,DB00178,Ramipril
,1725020,peak concentrations,"Mean peak concentrations of ramiprilat (the active diacid) were 11.5 ng/ml acutely, 18.5 ng/ml at 1 month, and 31.3 ng/ml at 1 year, and these were all statistically significantly different.",The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725020/),[ng] / [ml],11.5,3735,DB00178,Ramipril
,1725020,peak concentrations,"Mean peak concentrations of ramiprilat (the active diacid) were 11.5 ng/ml acutely, 18.5 ng/ml at 1 month, and 31.3 ng/ml at 1 year, and these were all statistically significantly different.",The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725020/),[ng] / [ml],18.5,3736,DB00178,Ramipril
,1725020,peak concentrations,"Mean peak concentrations of ramiprilat (the active diacid) were 11.5 ng/ml acutely, 18.5 ng/ml at 1 month, and 31.3 ng/ml at 1 year, and these were all statistically significantly different.",The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725020/),[ng] / [ml],31.3,3737,DB00178,Ramipril
,1725020,half-lives,"Mean half-lives of ramiprilat were 5.5 h acutely, 5.2 h at 1 month, and 4.6 h at 1 year, and these were not statistically significantly different.",The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725020/),h,5.5,3738,DB00178,Ramipril
,1725020,half-lives,"Mean half-lives of ramiprilat were 5.5 h acutely, 5.2 h at 1 month, and 4.6 h at 1 year, and these were not statistically significantly different.",The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725020/),h,5.2,3739,DB00178,Ramipril
,1725020,half-lives,"Mean half-lives of ramiprilat were 5.5 h acutely, 5.2 h at 1 month, and 4.6 h at 1 year, and these were not statistically significantly different.",The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725020/),h,4.6,3740,DB00178,Ramipril
,1725020,areas under the curve,"Mean areas under the curve excluding the component for saturable binding were 106.8 ng/h/ml acutely, 115.7 ng/h/ml at 1 month, and 248 ng/h/ml at 1 year; the latter was statistically significantly different from the earlier readings.",The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725020/),[ng] / [h·ml],106.8,3741,DB00178,Ramipril
,1725020,areas under the curve,"Mean areas under the curve excluding the component for saturable binding were 106.8 ng/h/ml acutely, 115.7 ng/h/ml at 1 month, and 248 ng/h/ml at 1 year; the latter was statistically significantly different from the earlier readings.",The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725020/),[ng] / [h·ml],115.7,3742,DB00178,Ramipril
,1725020,areas under the curve,"Mean areas under the curve excluding the component for saturable binding were 106.8 ng/h/ml acutely, 115.7 ng/h/ml at 1 month, and 248 ng/h/ml at 1 year; the latter was statistically significantly different from the earlier readings.",The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725020/),[ng] / [h·ml],248,3743,DB00178,Ramipril
,1725020,saturable binding,"Mean areas under the curve excluding the component for saturable binding were 106.8 ng/h/ml acutely, 115.7 ng/h/ml at 1 month, and 248 ng/h/ml at 1 year; the latter was statistically significantly different from the earlier readings.",The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725020/),[ng] / [h·ml],106.8,3744,DB00178,Ramipril
,1725020,saturable binding,"Mean areas under the curve excluding the component for saturable binding were 106.8 ng/h/ml acutely, 115.7 ng/h/ml at 1 month, and 248 ng/h/ml at 1 year; the latter was statistically significantly different from the earlier readings.",The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725020/),[ng] / [h·ml],115.7,3745,DB00178,Ramipril
,1725020,saturable binding,"Mean areas under the curve excluding the component for saturable binding were 106.8 ng/h/ml acutely, 115.7 ng/h/ml at 1 month, and 248 ng/h/ml at 1 year; the latter was statistically significantly different from the earlier readings.",The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725020/),[ng] / [h·ml],248,3746,DB00178,Ramipril
,2533075,initial apparent half-lives,"The mean initial apparent half-lives on Days 1 and 12, respectively, were 2.8 and 3.4 h (Group I: creatinine clearance 5-15 ml/min), 1.8 and 2.3 h (Group II: creatinine clearance 15-40 ml/min), and 1.9 and 1.9 h (Group III: creatinine clearance 40-80 ml/min).",Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533075/),h,2.8,22701,DB00178,Ramipril
,2533075,initial apparent half-lives,"The mean initial apparent half-lives on Days 1 and 12, respectively, were 2.8 and 3.4 h (Group I: creatinine clearance 5-15 ml/min), 1.8 and 2.3 h (Group II: creatinine clearance 15-40 ml/min), and 1.9 and 1.9 h (Group III: creatinine clearance 40-80 ml/min).",Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533075/),h,3.4,22702,DB00178,Ramipril
,2533075,initial apparent half-lives,"The mean initial apparent half-lives on Days 1 and 12, respectively, were 2.8 and 3.4 h (Group I: creatinine clearance 5-15 ml/min), 1.8 and 2.3 h (Group II: creatinine clearance 15-40 ml/min), and 1.9 and 1.9 h (Group III: creatinine clearance 40-80 ml/min).",Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533075/),h,1.8,22703,DB00178,Ramipril
,2533075,initial apparent half-lives,"The mean initial apparent half-lives on Days 1 and 12, respectively, were 2.8 and 3.4 h (Group I: creatinine clearance 5-15 ml/min), 1.8 and 2.3 h (Group II: creatinine clearance 15-40 ml/min), and 1.9 and 1.9 h (Group III: creatinine clearance 40-80 ml/min).",Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533075/),h,2.3,22704,DB00178,Ramipril
,2533075,initial apparent half-lives,"The mean initial apparent half-lives on Days 1 and 12, respectively, were 2.8 and 3.4 h (Group I: creatinine clearance 5-15 ml/min), 1.8 and 2.3 h (Group II: creatinine clearance 15-40 ml/min), and 1.9 and 1.9 h (Group III: creatinine clearance 40-80 ml/min).",Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533075/),h,1.9,22705,DB00178,Ramipril
,2533075,times to the peak plasma concentration,"The mean times to the peak plasma concentration were 5.7 h in Group I, 4.4 h in Group II and 3.8 h in Group III.",Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533075/),h,5.7,22706,DB00178,Ramipril
,2533075,times to the peak plasma concentration,"The mean times to the peak plasma concentration were 5.7 h in Group I, 4.4 h in Group II and 3.8 h in Group III.",Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533075/),h,4.4,22707,DB00178,Ramipril
,2533075,times to the peak plasma concentration,"The mean times to the peak plasma concentration were 5.7 h in Group I, 4.4 h in Group II and 3.8 h in Group III.",Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533075/),h,3.8,22708,DB00178,Ramipril
,2533075,initial apparent half-lives,"The initial decline in plasma ramiprilat was dependent upon renal function; the mean initial apparent half-lives (Days 1 and 12, respectively) were 16.0 and 14.8 h (Group I), 10.1 and 9.5 h (Group II) and 10.6 and 8.0 h (Group III).",Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533075/),h,16.0,22709,DB00178,Ramipril
,2533075,initial apparent half-lives,"The initial decline in plasma ramiprilat was dependent upon renal function; the mean initial apparent half-lives (Days 1 and 12, respectively) were 16.0 and 14.8 h (Group I), 10.1 and 9.5 h (Group II) and 10.6 and 8.0 h (Group III).",Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533075/),h,14.8,22710,DB00178,Ramipril
,2533075,initial apparent half-lives,"The initial decline in plasma ramiprilat was dependent upon renal function; the mean initial apparent half-lives (Days 1 and 12, respectively) were 16.0 and 14.8 h (Group I), 10.1 and 9.5 h (Group II) and 10.6 and 8.0 h (Group III).",Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533075/),h,10.1,22711,DB00178,Ramipril
,2533075,initial apparent half-lives,"The initial decline in plasma ramiprilat was dependent upon renal function; the mean initial apparent half-lives (Days 1 and 12, respectively) were 16.0 and 14.8 h (Group I), 10.1 and 9.5 h (Group II) and 10.6 and 8.0 h (Group III).",Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533075/),h,9.5,22712,DB00178,Ramipril
,2533075,initial apparent half-lives,"The initial decline in plasma ramiprilat was dependent upon renal function; the mean initial apparent half-lives (Days 1 and 12, respectively) were 16.0 and 14.8 h (Group I), 10.1 and 9.5 h (Group II) and 10.6 and 8.0 h (Group III).",Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533075/),h,10.6,22713,DB00178,Ramipril
,2533075,initial apparent half-lives,"The initial decline in plasma ramiprilat was dependent upon renal function; the mean initial apparent half-lives (Days 1 and 12, respectively) were 16.0 and 14.8 h (Group I), 10.1 and 9.5 h (Group II) and 10.6 and 8.0 h (Group III).",Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533075/),h,8.0,22714,DB00178,Ramipril
,7555035,Peak concentrations,Peak concentrations of ramiprilat in plasma (8.7 +/- 1.6 ng/ml) were reached after about 8 hours.,"Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555035/),[ng] / [ml],8.7,45168,DB00178,Ramipril
,7555035,AUC0-8,"AUC0-8 and AUC0-24-values were 36.5 and 111.9 ng.h/ml, respectively.","Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555035/),[h·ng] / [ml],36.5,45169,DB00178,Ramipril
,7555035,AUC0-24,"AUC0-8 and AUC0-24-values were 36.5 and 111.9 ng.h/ml, respectively.","Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555035/),[h·ng] / [ml],111.9,45170,DB00178,Ramipril
,7555035,fractions,"The main fractions excreted in the urine were diketopiperazine acid and ramiprilat amounting to 13.2 +/- 5.6 and 4.4 +/- 2.4%, respectively, of the dose administered.","Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555035/),%,13.2,45171,DB00178,Ramipril
,7555035,fractions,"The main fractions excreted in the urine were diketopiperazine acid and ramiprilat amounting to 13.2 +/- 5.6 and 4.4 +/- 2.4%, respectively, of the dose administered.","Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555035/),%,4.4,45172,DB00178,Ramipril
,7555035,fractions,"The main fractions excreted in the bile were diketopiperazine acid, ramiprilat glucuronide and diketopiperazine, 9.0 +/- 5.3, 3.4 +/- 4.2 and 2.0 +/- 1.2% in 24 hours, respectively, of the dose administered.","Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555035/),%,9.0,45173,DB00178,Ramipril
,7555035,fractions,"The main fractions excreted in the bile were diketopiperazine acid, ramiprilat glucuronide and diketopiperazine, 9.0 +/- 5.3, 3.4 +/- 4.2 and 2.0 +/- 1.2% in 24 hours, respectively, of the dose administered.","Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555035/),%,3.4,45174,DB00178,Ramipril
,7555035,fractions,"The main fractions excreted in the bile were diketopiperazine acid, ramiprilat glucuronide and diketopiperazine, 9.0 +/- 5.3, 3.4 +/- 4.2 and 2.0 +/- 1.2% in 24 hours, respectively, of the dose administered.","Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555035/),%,2.0,45175,DB00178,Ramipril
,16502769,limit of quantification,"The limit of quantification was 0.2 ng x ml(-1) and 1.0 ng x ml(-1) for ramipril and ramiprilat, respectively.",Comparative bioavailability of two ramipril formulations after single-dose administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502769/),[ng] / [ml],0.2,62887,DB00178,Ramipril
,16502769,limit of quantification,"The limit of quantification was 0.2 ng x ml(-1) and 1.0 ng x ml(-1) for ramipril and ramiprilat, respectively.",Comparative bioavailability of two ramipril formulations after single-dose administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502769/),[ng] / [ml],1.0,62888,DB00178,Ramipril
,7514239,Peak concentrations,"Peak concentrations of the active substance ramiprilat were reached after about 4 h and amounted to 22.3 +/- 11.1 ng/ml after the first dose, and a peak concentration of 26.6 +/- 10.0 ng/ml was observed 2.5 +/- 1.4 h on average after administration on day 14.",Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7514239/),[ng] / [ml],22.3,72887,DB00178,Ramipril
,7514239,peak concentration,"Peak concentrations of the active substance ramiprilat were reached after about 4 h and amounted to 22.3 +/- 11.1 ng/ml after the first dose, and a peak concentration of 26.6 +/- 10.0 ng/ml was observed 2.5 +/- 1.4 h on average after administration on day 14.",Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7514239/),[ng] / [ml],26.6,72888,DB00178,Ramipril
,7514239,AUD (0-24 h),Practically no accumulation was observed for ramiprilat; the AUD (0-24 h) values increased from 191.3 +/- 83.1 ng.h/ml for the first study day to 238.3 +/- 98.0 ng.h/ml for day 14.,Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7514239/),[h·ng] / [ml],191.3,72889,DB00178,Ramipril
,7514239,AUD (0-24 h),Practically no accumulation was observed for ramiprilat; the AUD (0-24 h) values increased from 191.3 +/- 83.1 ng.h/ml for the first study day to 238.3 +/- 98.0 ng.h/ml for day 14.,Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7514239/),[h·ng] / [ml],238.3,72890,DB00178,Ramipril
,16181761,recoveries,The recoveries of ramipril and ramiprilat from serum were in the range of 81.0-98.2%.,High-performance liquid chromatography-mass spectrometric analysis of ramipril and its active metabolite ramiprilat in human serum: application to a pharmacokinetic study in the Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16181761/),%,81.0-98.2,76277,DB00178,Ramipril
,20629042,flow rate,"The reconstituted samples were chromatographed on C(18) column by pumping 0.1% formic acid-acetonitrile (15:85, v/v) at a flow rate of 1 mL/min.","Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20629042/),[ml] / [min],1,77437,DB00178,Ramipril
,20629042,run time,A run time of 2.5 min for each sample made it possible to analyze more than 400 human plasma samples per day.,"Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20629042/),min,2.5,77438,DB00178,Ramipril
,6097271,maximum blood levels,"After oral administration, 2 mg/kg in rat and dog, 10 mg in man, of the carbon-14-labeled angiotensin I converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498), absorption (rat 56%, dog 43%, man 56%) occurred rapidly and induced maximum blood levels between 0.25 and 1 h.","Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6097271/),h,0.25,83652,DB00178,Ramipril
,6097271,half-lives,"The radioactivity disappeared from the blood in one or two phases with half-lives of 0.6 h in the rat, 1/3.8 h in dog and 0.5/2.9 h in man.","Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6097271/),h,0.6,83653,DB00178,Ramipril
,6097271,half-lives,"The radioactivity disappeared from the blood in one or two phases with half-lives of 0.6 h in the rat, 1/3.8 h in dog and 0.5/2.9 h in man.","Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6097271/),h,1/3.8,83654,DB00178,Ramipril
,6097271,half-lives,"The radioactivity disappeared from the blood in one or two phases with half-lives of 0.6 h in the rat, 1/3.8 h in dog and 0.5/2.9 h in man.","Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6097271/),h,0.5/,83655,DB00178,Ramipril
,6097271,half-lives,"The radioactivity disappeared from the blood in one or two phases with half-lives of 0.6 h in the rat, 1/3.8 h in dog and 0.5/2.9 h in man.","Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6097271/),h,2.9,83656,DB00178,Ramipril
,6097271,half-life,"The elimination from the lungs, which showed the highest concentrations until 5 d after administration, occurred with a half-life of 63 h.","Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6097271/),h,63,83657,DB00178,Ramipril
,6097271,radioactivity,"The radioactivity recovered from the urine of dogs amounted to 15%, that recovered from the feces amounted to 79%.","Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6097271/),%,15,83658,DB00178,Ramipril
,6097271,radioactivity,"The radioactivity recovered from the urine of dogs amounted to 15%, that recovered from the feces amounted to 79%.","Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6097271/),%,79,83659,DB00178,Ramipril
,27436437,initial,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86365,DB00178,Ramipril
,27436437,peak apixaban concentration,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86366,DB00178,Ramipril
,27436437,elimination half-life,Apixaban elimination appeared to display first-order kinetics with an elimination half-life of 7.4 h.,Anti-Xa activity in apixaban overdose: a case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),h,7.4,86367,DB00178,Ramipril
,26639833,Systemic bioavailability,Systemic bioavailability of ramiprilat after PO ramipril was 6-9%.,Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639833/),%,6-9,105845,DB00178,Ramipril
,26639833,Per,"Percentages of maximum ACE inhibitions from baseline were 98.88 (IV ramipril), 5.31 (placebo) and 27.68, 39.27, 46.67, 76.13 and 84.27 (the five doses of PO ramipril).",Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639833/),,98.88,105846,DB00178,Ramipril
,26639833,Per,"Percentages of maximum ACE inhibitions from baseline were 98.88 (IV ramipril), 5.31 (placebo) and 27.68, 39.27, 46.67, 76.13 and 84.27 (the five doses of PO ramipril).",Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639833/),,5.31,105847,DB00178,Ramipril
,26639833,Per,"Percentages of maximum ACE inhibitions from baseline were 98.88 (IV ramipril), 5.31 (placebo) and 27.68, 39.27, 46.67, 76.13 and 84.27 (the five doses of PO ramipril).",Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639833/),,27.68,105848,DB00178,Ramipril
,26639833,Per,"Percentages of maximum ACE inhibitions from baseline were 98.88 (IV ramipril), 5.31 (placebo) and 27.68, 39.27, 46.67, 76.13 and 84.27 (the five doses of PO ramipril).",Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639833/),,39.27,105849,DB00178,Ramipril
,26639833,Per,"Percentages of maximum ACE inhibitions from baseline were 98.88 (IV ramipril), 5.31 (placebo) and 27.68, 39.27, 46.67, 76.13 and 84.27 (the five doses of PO ramipril).",Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639833/),,46.67,105850,DB00178,Ramipril
,26639833,Per,"Percentages of maximum ACE inhibitions from baseline were 98.88 (IV ramipril), 5.31 (placebo) and 27.68, 39.27, 46.67, 76.13 and 84.27 (the five doses of PO ramipril).",Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639833/),,76.13,105851,DB00178,Ramipril
,26639833,Per,"Percentages of maximum ACE inhibitions from baseline were 98.88 (IV ramipril), 5.31 (placebo) and 27.68, 39.27, 46.67, 76.13 and 84.27 (the five doses of PO ramipril).",Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639833/),,84.27,105852,DB00178,Ramipril
,17127045,v,"The composition of optimized formulation was Sefsol 218 (20% w/w), Tween 80 (18% w/w), Carbitol (18% w/w) and standard buffer solution pH 5 (44% w/w) as oil, surfactant, cosurfactant and aqueous phase, respectively, containing 5 mg of ramipril showing drug release (95%), droplet size (80.9 nm), polydispersity (0.271), viscosity (10.68 cP), and infinite dilution capability.",Development and bioavailability assessment of ramipril nanoemulsion formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127045/),cp,10.68,108085,DB00178,Ramipril
,17127045,relative bioavailability,The relative bioavailability of ramipril nanoemulsion to that of conventional capsule form was found to be 229.62% whereas to that of drug suspension was 539.49%.,Development and bioavailability assessment of ramipril nanoemulsion formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127045/),%,229.62,108086,DB00178,Ramipril
,17127045,relative bioavailability,The relative bioavailability of ramipril nanoemulsion to that of conventional capsule form was found to be 229.62% whereas to that of drug suspension was 539.49%.,Development and bioavailability assessment of ramipril nanoemulsion formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127045/),%,539.49,108087,DB00178,Ramipril
,25632296,"area under the curve of plasma concentration, τ","Zofenopril/zofenoprilat PK analysis showed higher area under the curve of plasma concentration, τ values (ng/ml x h) than ramipril/ramiprilat (zofenopril vs. ramipril, 84.25 ± 34.47 vs. 47.40 ± 21.30; and zofenoprilat vs. ramiprilat, 653.67 ± 174.91 vs. 182.26 ± 61.28).",A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25632296/),[ng] / [h·ml],84.25,118464,DB00178,Ramipril
,25632296,"area under the curve of plasma concentration, τ","Zofenopril/zofenoprilat PK analysis showed higher area under the curve of plasma concentration, τ values (ng/ml x h) than ramipril/ramiprilat (zofenopril vs. ramipril, 84.25 ± 34.47 vs. 47.40 ± 21.30; and zofenoprilat vs. ramiprilat, 653.67 ± 174.91 vs. 182.26 ± 61.28).",A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25632296/),[ng] / [h·ml],47.40,118465,DB00178,Ramipril
,25632296,"area under the curve of plasma concentration, τ","Zofenopril/zofenoprilat PK analysis showed higher area under the curve of plasma concentration, τ values (ng/ml x h) than ramipril/ramiprilat (zofenopril vs. ramipril, 84.25 ± 34.47 vs. 47.40 ± 21.30; and zofenoprilat vs. ramiprilat, 653.67 ± 174.91 vs. 182.26 ± 61.28).",A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25632296/),[ng] / [h·ml],653.67,118466,DB00178,Ramipril
,25632296,"area under the curve of plasma concentration, τ","Zofenopril/zofenoprilat PK analysis showed higher area under the curve of plasma concentration, τ values (ng/ml x h) than ramipril/ramiprilat (zofenopril vs. ramipril, 84.25 ± 34.47 vs. 47.40 ± 21.30; and zofenoprilat vs. ramiprilat, 653.67 ± 174.91 vs. 182.26 ± 61.28).",A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25632296/),[ng] / [h·ml],182.26,118467,DB00178,Ramipril
>,29897424,extraction recovery,"The mean extraction recovery for analytes and ISs were >(86.0%), consistent across all four QC levels.",Challenges in Simultaneous Determination of Hydrochlorothiazide and Ramipril in Human Plasma: Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897424/),%,86.0,128528,DB00178,Ramipril
,22339447,absolute bioavailability,"Following oral administration, vildagliptin is rapidly and well absorbed with an absolute bioavailability of 85%.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),%,85,128972,DB00178,Ramipril
,22339447,volume of distribution,"Vildagliptin is minimally bound to plasma proteins (9.3%) and, on the basis of a volume of distribution of 71 L, it is considered to distribute extensively into extravascular spaces.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),l,71,128973,DB00178,Ramipril
,22339447,Renal clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],13,128974,DB00178,Ramipril
,22339447,total body clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],41,128975,DB00178,Ramipril
,22339447,IC(50)),"Vildagliptin is a potent inhibitor of the DPP-4 enzyme, with a concentration required to achieve 50% DPP-4 inhibition (IC(50)) of 4.5 nmol/L in patients with T2DM.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[nM] / [l],4.5,128976,DB00178,Ramipril
,15918521,retention time,"Imidapril was detected as m/z 406 at a retention time of ca. 2.3 min, and ramipril as m/z 417 at ca. 3.6 min.",LC-MS determination and bioavailability study of imidapril hydrochloride after the oral administration of imidapril tablets in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918521/),min,2.3,130840,DB00178,Ramipril
,15918521,retention time,"Imidapril was detected as m/z 406 at a retention time of ca. 2.3 min, and ramipril as m/z 417 at ca. 3.6 min.",LC-MS determination and bioavailability study of imidapril hydrochloride after the oral administration of imidapril tablets in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918521/),min,3,130841,DB00178,Ramipril
,15918521,AUC12hr,"The plasma concentration-versus-time curves of eight healthy male volunteers administered a single dose of imidapril (10 mg), gave an AUC12hr of imidapril of 121.48 +/- 35.81 ng mL(-1) h, and Cmax and Tmax values of 32.59 +/- 9.76 ng/mL and 1.75 +/- 0.27 h.",LC-MS determination and bioavailability study of imidapril hydrochloride after the oral administration of imidapril tablets in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918521/),[h·ng] / [ml],121.48,130842,DB00178,Ramipril
,15918521,Cmax,"The plasma concentration-versus-time curves of eight healthy male volunteers administered a single dose of imidapril (10 mg), gave an AUC12hr of imidapril of 121.48 +/- 35.81 ng mL(-1) h, and Cmax and Tmax values of 32.59 +/- 9.76 ng/mL and 1.75 +/- 0.27 h.",LC-MS determination and bioavailability study of imidapril hydrochloride after the oral administration of imidapril tablets in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918521/),[ng] / [ml],32.59,130843,DB00178,Ramipril
,15918521,Tmax,"The plasma concentration-versus-time curves of eight healthy male volunteers administered a single dose of imidapril (10 mg), gave an AUC12hr of imidapril of 121.48 +/- 35.81 ng mL(-1) h, and Cmax and Tmax values of 32.59 +/- 9.76 ng/mL and 1.75 +/- 0.27 h.",LC-MS determination and bioavailability study of imidapril hydrochloride after the oral administration of imidapril tablets in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918521/),h,1.75,130844,DB00178,Ramipril
,19813461,Tmax,Tmax of the test formulation was 0.67 +/- 0.33 h for ramipril and 2.28 +/- 0.74 h for ramiprilat; Tmax of the reference formulation was 0.71 +/- 0.32 h for ramipril and 2.40 +/- 0.88 for ramiprilat.,Bioequivalence study of two tablet formulations of ramipril in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19813461/),h,0.67,136034,DB00178,Ramipril
,19813461,Tmax,Tmax of the test formulation was 0.67 +/- 0.33 h for ramipril and 2.28 +/- 0.74 h for ramiprilat; Tmax of the reference formulation was 0.71 +/- 0.32 h for ramipril and 2.40 +/- 0.88 for ramiprilat.,Bioequivalence study of two tablet formulations of ramipril in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19813461/),h,2.28,136035,DB00178,Ramipril
,19813461,Tmax,Tmax of the test formulation was 0.67 +/- 0.33 h for ramipril and 2.28 +/- 0.74 h for ramiprilat; Tmax of the reference formulation was 0.71 +/- 0.32 h for ramipril and 2.40 +/- 0.88 for ramiprilat.,Bioequivalence study of two tablet formulations of ramipril in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19813461/),h,0.71,136036,DB00178,Ramipril
,19813461,Tmax,Tmax of the test formulation was 0.67 +/- 0.33 h for ramipril and 2.28 +/- 0.74 h for ramiprilat; Tmax of the reference formulation was 0.71 +/- 0.32 h for ramipril and 2.40 +/- 0.88 for ramiprilat.,Bioequivalence study of two tablet formulations of ramipril in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19813461/),,2.40,136037,DB00178,Ramipril
,2474102,maximal plasma level,The maximal plasma level of ramipril was 57.0 +/- 26.8 ng/ml after 1.4 h; t1/2 was 2.4 +/- 1.2 h.,Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2474102/),[ng] / [ml],57.0,143088,DB00178,Ramipril
,2474102,t1/2,The maximal plasma level of ramipril was 57.0 +/- 26.8 ng/ml after 1.4 h; t1/2 was 2.4 +/- 1.2 h.,Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2474102/),h,2.4,143089,DB00178,Ramipril
,2474102,peak level,The peak level of ramiprilat was 27.9 +/- 24 ng/ml after 4.6 h; t1/2 for the active compound was 6 +/- 4.2 h.,Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2474102/),[ng] / [ml],27.9,143090,DB00178,Ramipril
,2474102,t1/2,The peak level of ramiprilat was 27.9 +/- 24 ng/ml after 4.6 h; t1/2 for the active compound was 6 +/- 4.2 h.,Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2474102/),h,6,143091,DB00178,Ramipril
,2474102,total recovery,The total recovery of ramipril and metabolites in urine was on average 39 +/- 17.5% within 96 h.,Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2474102/),%,39,143092,DB00178,Ramipril
,28189955,detection limits,Linear calibration ranges were obtained in the range 0.05-2.0μgmL-1 for FLD and MET and 0.1-2.0μgmL-1 for RAM with detection limits of 0.013-0.031μgmL-1 for all the studied drug combinations.,Ultrasound assisted dispersive liquid-liquid microextraction coupled with high performance liquid chromatography designated for bioavailability studies of felodipine combinations in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28189955/),1/[μgml],0.013-0.031,147977,DB00178,Ramipril
,3000393,sensitivity,"The sensitivity of the assay was 0.1 and 0.5 ng/ml for diacid and ramipril, respectively.",A radioimmunoassay for the angiotensin converting enzyme inhibitor ramipril and its active metabolite. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3000393/),[ng] / [ml],0.1,152327,DB00178,Ramipril
,3000393,sensitivity,"The sensitivity of the assay was 0.1 and 0.5 ng/ml for diacid and ramipril, respectively.",A radioimmunoassay for the angiotensin converting enzyme inhibitor ramipril and its active metabolite. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3000393/),[ng] / [ml],0.5,152328,DB00178,Ramipril
,3034035,trough levels,"Mean serum digoxin concentration was not significantly influenced by ramipril coadministration with trough levels of 0.90 +/- 0.24 before, 0.93 +/- 0.38 during and 0.82 +/- 0.33 ng/ml after ramipril medication.",Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034035/),[ng] / [ml],0.90,154703,DB00178,Ramipril
,3034035,trough levels,"Mean serum digoxin concentration was not significantly influenced by ramipril coadministration with trough levels of 0.90 +/- 0.24 before, 0.93 +/- 0.38 during and 0.82 +/- 0.33 ng/ml after ramipril medication.",Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034035/),[ng] / [ml],0.93,154704,DB00178,Ramipril
,3034035,trough levels,"Mean serum digoxin concentration was not significantly influenced by ramipril coadministration with trough levels of 0.90 +/- 0.24 before, 0.93 +/- 0.38 during and 0.82 +/- 0.33 ng/ml after ramipril medication.",Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034035/),[ng] / [ml],0.82,154705,DB00178,Ramipril
,8276048,maximal degree of,"The mean maximal degree of ACE inhibition was 73.2, 90.4 and 98.5%, respectively, after the three doses of ramipril.",Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276048/),%,73.2,157384,DB00178,Ramipril
,8276048,maximal degree of,"The mean maximal degree of ACE inhibition was 73.2, 90.4 and 98.5%, respectively, after the three doses of ramipril.",Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276048/),%,90.4,157385,DB00178,Ramipril
,8276048,maximal degree of,"The mean maximal degree of ACE inhibition was 73.2, 90.4 and 98.5%, respectively, after the three doses of ramipril.",Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276048/),%,98.5,157386,DB00178,Ramipril
,8276048,half life,The degree of inhibition declined with a half life of about 75 h.,Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276048/),h,75,157387,DB00178,Ramipril
,7768254,absolute bioavailability,"The absolute bioavailability as judged by ramipril plasma AUC was 15%, by ramiprilat plasma AUC, 44%.","Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768254/),%,15,158076,DB00178,Ramipril
,7768254,absolute bioavailability,"The absolute bioavailability as judged by ramipril plasma AUC was 15%, by ramiprilat plasma AUC, 44%.","Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768254/),%,44,158077,DB00178,Ramipril
,7768254,Urinary recovery,"Urinary recovery of oral ramipril was 23%, i.v. ramipril 49%, and i.v. ramiprilat 68% of the given dose.","Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768254/),%,23,158078,DB00178,Ramipril
,7768254,Urinary recovery,"Urinary recovery of oral ramipril was 23%, i.v. ramipril 49%, and i.v. ramiprilat 68% of the given dose.","Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768254/),%,49,158079,DB00178,Ramipril
,7768254,Urinary recovery,"Urinary recovery of oral ramipril was 23%, i.v. ramipril 49%, and i.v. ramiprilat 68% of the given dose.","Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768254/),%,68,158080,DB00178,Ramipril
,7768254,bioavailability,It is concluded that the bioavailability of oral ramipril seems to be in the range of 44-66%.,"Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768254/),%,44-66,158081,DB00178,Ramipril
,1725018,concentrations,"The highest concentrations in bile were found for diketopiperazine acid (3,080 ng/ml) and ramipril glucuronide (2,414 ng/ml).",Preliminary results of biliary excretion of ramipril after T-drainage in cholecystectomy patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725018/),[ng] / [ml],"3,080",158198,DB00178,Ramipril
,1725018,concentrations,"The highest concentrations in bile were found for diketopiperazine acid (3,080 ng/ml) and ramipril glucuronide (2,414 ng/ml).",Preliminary results of biliary excretion of ramipril after T-drainage in cholecystectomy patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725018/),[ng] / [ml],"2,414",158199,DB00178,Ramipril
,8137599,protein binding,"In the therapeutic concentration range, protein binding of ramipril and ramiprilat is 73 and 56%, respectively.",Clinical pharmacokinetics of ramipril. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137599/),%,73,182490,DB00178,Ramipril
,8137599,protein binding,"In the therapeutic concentration range, protein binding of ramipril and ramiprilat is 73 and 56%, respectively.",Clinical pharmacokinetics of ramipril. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137599/),%,56,182491,DB00178,Ramipril
,8137599,half-life,Elimination from the body is characterised by a relatively rapid initial phase with a half-life of 7 hours and a late phase with a half-life of about 120 hours.,Clinical pharmacokinetics of ramipril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137599/),h,7,182492,DB00178,Ramipril
,8137599,half-life,Elimination from the body is characterised by a relatively rapid initial phase with a half-life of 7 hours and a late phase with a half-life of about 120 hours.,Clinical pharmacokinetics of ramipril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137599/),h,120,182493,DB00178,Ramipril
,26839805,flow rate,"After solid phase extraction (SPE), analytes and ISs were separated on an Agilent Poroshell 120, EC-C18 (50 mm × 4.6 mm, i.d., 2.7 μm) column with a mobile phase consisting of methanol/water (85:15, v/v) containing 5 mmol/L ammonium formate and 0.1% formic acid at a flow rate of 0.4 mL/min.","Simultaneous Determination and Pharmacokinetic Study of Losartan, Losartan Carboxylic Acid, Ramipril, Ramiprilat, and Hydrochlorothiazide in Rat Plasma by a Liquid Chromatography/Tandem Mass Spectrometry Method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26839805/),[ml] / [min],0.4,182648,DB00178,Ramipril
,18307734,bioavailability,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),%,2.6 and 5.0,185713,DB00178,Ramipril
,18307734,IC50,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),[nM] / [l],0.6,185714,DB00178,Ramipril
,18307734,plasma half-life,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),h,23-36,185715,DB00178,Ramipril
,7875191,AUC,"The mean AUC of ramipril for ramipril+placebo (R+P) and ramipril+simvastatin (R+S) was 22.2 and 21.3 ng.h.ml-1, respectively; for ramiprilat the corresponding figures were 61.3 and 57.6 ng.h.ml-1.",Lack of interaction between ramipril and simvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),[h·ng] / [ml],22.2,192219,DB00178,Ramipril
,7875191,AUC,"The mean AUC of ramipril for ramipril+placebo (R+P) and ramipril+simvastatin (R+S) was 22.2 and 21.3 ng.h.ml-1, respectively; for ramiprilat the corresponding figures were 61.3 and 57.6 ng.h.ml-1.",Lack of interaction between ramipril and simvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),[h·ng] / [ml],21.3,192220,DB00178,Ramipril
,7875191,AUC,"The mean AUC of ramipril for ramipril+placebo (R+P) and ramipril+simvastatin (R+S) was 22.2 and 21.3 ng.h.ml-1, respectively; for ramiprilat the corresponding figures were 61.3 and 57.6 ng.h.ml-1.",Lack of interaction between ramipril and simvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),[h·ng] / [ml],61.3,192221,DB00178,Ramipril
,7875191,AUC,"The mean AUC of ramipril for ramipril+placebo (R+P) and ramipril+simvastatin (R+S) was 22.2 and 21.3 ng.h.ml-1, respectively; for ramiprilat the corresponding figures were 61.3 and 57.6 ng.h.ml-1.",Lack of interaction between ramipril and simvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),[h·ng] / [ml],57.6,192222,DB00178,Ramipril
,7875191,urinary excretion,The urinary excretion of ramipril+metabolites for (R+P) and (R+S) was 25.2 and 24.1% of dose.,Lack of interaction between ramipril and simvastatin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),%,25.2,192223,DB00178,Ramipril
,7875191,urinary excretion,The urinary excretion of ramipril+metabolites for (R+P) and (R+S) was 25.2 and 24.1% of dose.,Lack of interaction between ramipril and simvastatin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),%,24.1,192224,DB00178,Ramipril
,7875191,maximum percentage inhibition,"The maximum percentage inhibition of ACE-activity for (R+P) was 94.6%, and for (R+S) it was 94.1%.",Lack of interaction between ramipril and simvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),%,94.6,192225,DB00178,Ramipril
,7875191,maximum percentage inhibition,"The maximum percentage inhibition of ACE-activity for (R+P) was 94.6%, and for (R+S) it was 94.1%.",Lack of interaction between ramipril and simvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),%,94.1,192226,DB00178,Ramipril
,11284442,renal,"Ramipril decreased renal lithium clearance (90+/-8 vs. 142+/-10 microl/min/100 g, P<0.001, n=24) and increased the fractional lithium reabsorption (74.3+/-1.9 vs. 66.7+/-1.7%, P<0.05) and plasma lithium concentration (0.108+/-0.006 vs. 0.085+/-0.004 mM, P<0.01).",Effects of icatibant on the ramipril-induced decreased in renal lithium clearance in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11284442/),[μl] / [100·g·min],90,202267,DB00178,Ramipril
,11284442,renal,"Ramipril decreased renal lithium clearance (90+/-8 vs. 142+/-10 microl/min/100 g, P<0.001, n=24) and increased the fractional lithium reabsorption (74.3+/-1.9 vs. 66.7+/-1.7%, P<0.05) and plasma lithium concentration (0.108+/-0.006 vs. 0.085+/-0.004 mM, P<0.01).",Effects of icatibant on the ramipril-induced decreased in renal lithium clearance in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11284442/),[μl] / [100·g·min],142,202268,DB00178,Ramipril
,11284442,clearance,"Icatibant had no effect per se on renal function but attenuated the ramipril-induced decrease in renal lithium clearance (118+/-16 vs. 90+/-8 microl/min/100 g, n=12 and 24 respectively, P<0.05 one-tailed test) and systolic blood pressure.",Effects of icatibant on the ramipril-induced decreased in renal lithium clearance in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11284442/),[μl] / [100·g·min],118,202269,DB00178,Ramipril
,11284442,clearance,"Icatibant had no effect per se on renal function but attenuated the ramipril-induced decrease in renal lithium clearance (118+/-16 vs. 90+/-8 microl/min/100 g, n=12 and 24 respectively, P<0.05 one-tailed test) and systolic blood pressure.",Effects of icatibant on the ramipril-induced decreased in renal lithium clearance in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11284442/),[μl] / [100·g·min],90,202270,DB00178,Ramipril
,3034031,peak concentrations,HOE 498 reached peak concentrations of 62.4 +/- 23.3 ng/ml in serum after 0.7 +/- 0.3 hours.,Pharmacokinetics of ramipril in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034031/),[ng] / [ml],62.4,204706,DB00178,Ramipril
,3034031,apparent half-life,Serum levels decreased with an apparent half-life of 0.9 +/- 0.4 hours.,Pharmacokinetics of ramipril in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034031/),h,0.9,204707,DB00178,Ramipril
,3034031,peak concentrations,"The diacid was rapidly formed in serum, reaching peak concentrations of 40.6 +/- 14.0 ng/ml after 2.0 +/- 0.6 hours and declining with a half-life of 2.2 +/- 0.5 hours.",Pharmacokinetics of ramipril in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034031/),[ng] / [ml],40.6,204708,DB00178,Ramipril
,3034031,half-life,"The diacid was rapidly formed in serum, reaching peak concentrations of 40.6 +/- 14.0 ng/ml after 2.0 +/- 0.6 hours and declining with a half-life of 2.2 +/- 0.5 hours.",Pharmacokinetics of ramipril in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034031/),h,2.2,204709,DB00178,Ramipril
,3034031,recovery,"The mean recovery of HOE 498 and metabolites in urine, up to 26 hours after administration, was 35 +/- 14% of the dose.",Pharmacokinetics of ramipril in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034031/),%,35,204710,DB00178,Ramipril
,3034031,apparent half-lives,"The apparent half-lives, calculated from urine parameters, for HOE 498 and the diacid were 2.6 +/- 0.9 and 4.0 +/- 1.1 hours, respectively.",Pharmacokinetics of ramipril in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034031/),h,2.6,204711,DB00178,Ramipril
,3034031,apparent half-lives,"The apparent half-lives, calculated from urine parameters, for HOE 498 and the diacid were 2.6 +/- 0.9 and 4.0 +/- 1.1 hours, respectively.",Pharmacokinetics of ramipril in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034031/),h,4.0,204712,DB00178,Ramipril
,8720427,maximal concentration,"Long-term administration of ramipril did not modify the time to peak ramiprilat concentration, but increased the mean maximal concentration significantly: 20.2 +/- 12.7 vs. 10.4 +/- 7.1 ng center dot ml-1.","Kinetics, safety, and efficacy of ramipril after long-term administration in hemodialyzed patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8720427/),[center·dot·ng] / [ml],20.2,206034,DB00178,Ramipril
,8720427,maximal concentration,"Long-term administration of ramipril did not modify the time to peak ramiprilat concentration, but increased the mean maximal concentration significantly: 20.2 +/- 12.7 vs. 10.4 +/- 7.1 ng center dot ml-1.","Kinetics, safety, and efficacy of ramipril after long-term administration in hemodialyzed patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8720427/),[center·dot·ng] / [ml],10.4,206035,DB00178,Ramipril
,8720427,accumulation ratio,The mean accumulation ratio was 2.2.,"Kinetics, safety, and efficacy of ramipril after long-term administration in hemodialyzed patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8720427/),,2.2,206036,DB00178,Ramipril
,8720427,clearance,Ramiprilat hemodialysis clearance was 31.7 ml/min (range 4.2-64.9 ml/min) on day 1 and 21.0 ml/min (range 7.9-56.5 ml/min) on day 29.,"Kinetics, safety, and efficacy of ramipril after long-term administration in hemodialyzed patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8720427/),[ml] / [min],31.7,206037,DB00178,Ramipril
,8720427,clearance,Ramiprilat hemodialysis clearance was 31.7 ml/min (range 4.2-64.9 ml/min) on day 1 and 21.0 ml/min (range 7.9-56.5 ml/min) on day 29.,"Kinetics, safety, and efficacy of ramipril after long-term administration in hemodialyzed patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8720427/),[ml] / [min],21.0,206038,DB00178,Ramipril
,29887764,t1/2β,"There is a group of subjects who showed a t1/2β of approximately 80 h (15% CV), and two apparent groups with a longer t1/2βfor each formulation (124 h, 22.5% CV; 166 h, 21.6% CV, respectively, p = 0.0013).",Lack of Male-Female Differences in Disposition and Esterase Hydrolysis of Ramipril to Ramiprilat in Healthy Volunteers after a Single Oral Dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29887764/),h,80,208158,DB00178,Ramipril
,29887764,t1/2β,"There is a group of subjects who showed a t1/2β of approximately 80 h (15% CV), and two apparent groups with a longer t1/2βfor each formulation (124 h, 22.5% CV; 166 h, 21.6% CV, respectively, p = 0.0013).",Lack of Male-Female Differences in Disposition and Esterase Hydrolysis of Ramipril to Ramiprilat in Healthy Volunteers after a Single Oral Dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29887764/),h,124,208159,DB00178,Ramipril
,29887764,t1/2β,"There is a group of subjects who showed a t1/2β of approximately 80 h (15% CV), and two apparent groups with a longer t1/2βfor each formulation (124 h, 22.5% CV; 166 h, 21.6% CV, respectively, p = 0.0013).",Lack of Male-Female Differences in Disposition and Esterase Hydrolysis of Ramipril to Ramiprilat in Healthy Volunteers after a Single Oral Dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29887764/),h,166,208160,DB00178,Ramipril
,7995323,peak plasma concentrations,"The peak plasma concentrations of ramipril and ramiprilat increased slightly (from 11.9 to 14.8 ng/ml, and from 6.39 to 8.96 ng/ml, respectively) as did the area under the plasma concentration-time curve of ramipril (0-4 h) and ramiprilat (0-24 h) (from 15.8 to 19.8 ng.ml-1.h, and from 63.4 to 74.6 ng.ml-1.h, respectively).",Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995323/),[ng] / [ml],11.9 to 14.8,208421,DB00178,Ramipril
,7995323,peak plasma concentrations,"The peak plasma concentrations of ramipril and ramiprilat increased slightly (from 11.9 to 14.8 ng/ml, and from 6.39 to 8.96 ng/ml, respectively) as did the area under the plasma concentration-time curve of ramipril (0-4 h) and ramiprilat (0-24 h) (from 15.8 to 19.8 ng.ml-1.h, and from 63.4 to 74.6 ng.ml-1.h, respectively).",Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995323/),[ng] / [ml],6.39 to 8.96,208422,DB00178,Ramipril
,7995323,area under the plasma concentration-time curve,"The peak plasma concentrations of ramipril and ramiprilat increased slightly (from 11.9 to 14.8 ng/ml, and from 6.39 to 8.96 ng/ml, respectively) as did the area under the plasma concentration-time curve of ramipril (0-4 h) and ramiprilat (0-24 h) (from 15.8 to 19.8 ng.ml-1.h, and from 63.4 to 74.6 ng.ml-1.h, respectively).",Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995323/),[h·ng] / [ml],15.8 to 19.8,208423,DB00178,Ramipril
,7995323,area under the plasma concentration-time curve,"The peak plasma concentrations of ramipril and ramiprilat increased slightly (from 11.9 to 14.8 ng/ml, and from 6.39 to 8.96 ng/ml, respectively) as did the area under the plasma concentration-time curve of ramipril (0-4 h) and ramiprilat (0-24 h) (from 15.8 to 19.8 ng.ml-1.h, and from 63.4 to 74.6 ng.ml-1.h, respectively).",Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995323/),[h·ng] / [ml],63.4 to 74.6,208424,DB00178,Ramipril
,7995323,urinary excretion,The urinary excretion of ramiprilat also rose (from 6.82 to 7.73% of dose) following simultaneous treatment with piretanide.,Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995323/),%,6.82,208425,DB00178,Ramipril
,7995323,urinary excretion,The urinary excretion of ramiprilat also rose (from 6.82 to 7.73% of dose) following simultaneous treatment with piretanide.,Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995323/),%,7.73,208426,DB00178,Ramipril
,7995323,peak plasma concentration,The peak plasma concentration of piretanide was somewhat reduced (from 285 to 244 ng/ml) following simultaneous treatment with ramipril.,Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995323/),[ng] / [ml],285 to 244,208427,DB00178,Ramipril
,16413241,cumulative excretion,"The 24-hour urine AcSDKP cumulative excretion increased significantly more after 25 mg AVE7688 (919 nmol [95% confidence interval (CI), 803-1052 nmol], P < .05) than after 5 mg AVE7688 (706 nmol [95% CI, 612-813 nmol]) or 10 mg ramipril (511 nmol [95% CI, 440-593 nmol]).",Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413241/),nM,919,226667,DB00178,Ramipril
,16413241,cumulative excretion,"The 24-hour urine AcSDKP cumulative excretion increased significantly more after 25 mg AVE7688 (919 nmol [95% confidence interval (CI), 803-1052 nmol], P < .05) than after 5 mg AVE7688 (706 nmol [95% CI, 612-813 nmol]) or 10 mg ramipril (511 nmol [95% CI, 440-593 nmol]).",Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413241/),nM,706,226668,DB00178,Ramipril
,16413241,cumulative excretion,"The 24-hour urine AcSDKP cumulative excretion increased significantly more after 25 mg AVE7688 (919 nmol [95% confidence interval (CI), 803-1052 nmol], P < .05) than after 5 mg AVE7688 (706 nmol [95% CI, 612-813 nmol]) or 10 mg ramipril (511 nmol [95% CI, 440-593 nmol]).",Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413241/),nM,511,226669,DB00178,Ramipril
,16413241,plasma active renin concentration,"In the low-salt panel the rise in plasma active renin concentration achieved 24 hours after dosing by 25 mg AVE7688 (247 pg/mL [95% CI, 157-389 pg/mL], P < .05) was significantly higher than that achieved by 5 mg AVE7688 (129 pg/mL [95% CI, 75-221 pg/mL]) or 10 mg ramipril (113 pg/mL [95% CI, 67-193 pg/mL]), which did not differ.",Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413241/),[pg] / [ml],247,226670,DB00178,Ramipril
,16413241,plasma active renin concentration,"In the low-salt panel the rise in plasma active renin concentration achieved 24 hours after dosing by 25 mg AVE7688 (247 pg/mL [95% CI, 157-389 pg/mL], P < .05) was significantly higher than that achieved by 5 mg AVE7688 (129 pg/mL [95% CI, 75-221 pg/mL]) or 10 mg ramipril (113 pg/mL [95% CI, 67-193 pg/mL]), which did not differ.",Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413241/),[pg] / [ml],129,226671,DB00178,Ramipril
,16413241,plasma active renin concentration,"In the low-salt panel the rise in plasma active renin concentration achieved 24 hours after dosing by 25 mg AVE7688 (247 pg/mL [95% CI, 157-389 pg/mL], P < .05) was significantly higher than that achieved by 5 mg AVE7688 (129 pg/mL [95% CI, 75-221 pg/mL]) or 10 mg ramipril (113 pg/mL [95% CI, 67-193 pg/mL]), which did not differ.",Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413241/),[pg] / [ml],113,226672,DB00178,Ramipril
,9150805,peak concentrations,After a single oral dose of 5 mg ramipril plasma levels of the parent compound reached peak concentrations of 48.6 +/- 39.8 ng/ml after 0.7 +/- 0.5 h and declined rapidly to 0.7 +/- 1.2 ng/ml after 8 h.,Angiotensin-converting enzyme inhibition in cirrhotic patients--pharmacokinetics of ramipril. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9150805/),[ng] / [ml],48.6,228570,DB00178,Ramipril
,9150805,peak concentrations,After a single oral dose of 5 mg ramipril plasma levels of the parent compound reached peak concentrations of 48.6 +/- 39.8 ng/ml after 0.7 +/- 0.5 h and declined rapidly to 0.7 +/- 1.2 ng/ml after 8 h.,Angiotensin-converting enzyme inhibition in cirrhotic patients--pharmacokinetics of ramipril. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9150805/),[ng] / [ml],0.7,228571,DB00178,Ramipril
,9150805,peak concentrations,"Plasma levels of ramiprilat reached peak concentrations of 3.8 +/- 2.9 ng/ml after 3.0 +/- 2.2 h, thereafter declined slowly and could be detected up to 240 h.",Angiotensin-converting enzyme inhibition in cirrhotic patients--pharmacokinetics of ramipril. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9150805/),[ng] / [ml],3.8,228572,DB00178,Ramipril
,9150805,total recovery,The total recovery of ramipril and metabolites in urine within 96 h was on average 46.0 +/- 10.9% of the administered dose.,Angiotensin-converting enzyme inhibition in cirrhotic patients--pharmacokinetics of ramipril. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9150805/),%,46.0,228573,DB00178,Ramipril
,3034036,peak serum concentrations,The original compound reached peak serum concentrations of 42.8 +/- 26.5 ng/ml about 1 hour after dosing and was completely eliminated from the serum after 24 hours.,Pharmacokinetics and pharmacodynamics of ramipril in renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034036/),[ng] / [ml],42.8,229866,DB00178,Ramipril
,3034036,peak values,Ramiprilat reached peak values of 14.4 +/- 11.6 ng/ml after about 6 hours.,Pharmacokinetics and pharmacodynamics of ramipril in renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034036/),[ng] / [ml],14.4,229867,DB00178,Ramipril
,14755115,t1/2beta,"There is a group of subjects who showed a t1/2beta of approximately 80 h (15% CV), and two apparent groups with a longer t1/2beta for each formulation (124 h, 22.5% CV; 166 h, 21.6% CV, respectively, p = 0.0013).",Lack of male-female differences in disposition and esterase hydrolysis of ramipril to ramiprilat in healthy volunteers after a single oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14755115/),h,80,234065,DB00178,Ramipril
,14755115,t1/2beta,"There is a group of subjects who showed a t1/2beta of approximately 80 h (15% CV), and two apparent groups with a longer t1/2beta for each formulation (124 h, 22.5% CV; 166 h, 21.6% CV, respectively, p = 0.0013).",Lack of male-female differences in disposition and esterase hydrolysis of ramipril to ramiprilat in healthy volunteers after a single oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14755115/),h,124,234066,DB00178,Ramipril
,14755115,t1/2beta,"There is a group of subjects who showed a t1/2beta of approximately 80 h (15% CV), and two apparent groups with a longer t1/2beta for each formulation (124 h, 22.5% CV; 166 h, 21.6% CV, respectively, p = 0.0013).",Lack of male-female differences in disposition and esterase hydrolysis of ramipril to ramiprilat in healthy volunteers after a single oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14755115/),h,166,234067,DB00178,Ramipril
,6097458,Peak serum concentration,Peak serum concentration of M 1 between 5-50 ng/ml was observed 1.5-3.0 h after administration.,Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6097458/),[ng] / [ml],5-50,250660,DB00178,Ramipril
,6097458,half-life,The serum concentration-time curve of M 1 was polyphasic and exhibited a prolonged terminal phase with a half-life of approximately 110 h.,Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6097458/),h,110,250661,DB00178,Ramipril
,18611061,absolute bioavailability,The absolute bioavailability of aliskiren is 2.6%.,Clinical pharmacokinetics and pharmacodynamics of aliskiren. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611061/),%,2.6,252071,DB00178,Ramipril
,18611061,accumulation factor,"Steady-state plasma concentrations of aliskiren are reached after 7-8 days of once-daily dosing, and the accumulation factor for aliskiren is approximately 2.",Clinical pharmacokinetics and pharmacodynamics of aliskiren. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611061/),,2,252072,DB00178,Ramipril
,17117442,linear dynamic,"The method exhibited a linear dynamic range of 20-10,000 pg/mL for both trandolapril and trandolaprilat in human plasma.",Quantification of trandolapril and its metabolite trandolaprilat in human plasma by liquid chromatography/tandem mass spectrometry using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17117442/),[pg] / [ml],"20-10,000",265160,DB00178,Ramipril
,17117442,run time,A run time of 2.0 min for each sample made it possible to analyze more than 400 human plasma samples per day.,Quantification of trandolapril and its metabolite trandolaprilat in human plasma by liquid chromatography/tandem mass spectrometry using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17117442/),min,2.0,265161,DB00178,Ramipril
,8331554,CSF/plasma (unbound) ratios,"The CSF/plasma (unbound) ratios of ramiprilat on day 7 were (mean +/- S.D.): 0.01 +/- 0.003 (2 h after dose), 0.18 +/- 0.05 (12 h after dose) and 0.32 +/- 0.11 (24 h after dose).",Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331554/),,0.01,267703,DB00178,Ramipril
,8331554,CSF/plasma (unbound) ratios,"The CSF/plasma (unbound) ratios of ramiprilat on day 7 were (mean +/- S.D.): 0.01 +/- 0.003 (2 h after dose), 0.18 +/- 0.05 (12 h after dose) and 0.32 +/- 0.11 (24 h after dose).",Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331554/),,0.18,267704,DB00178,Ramipril
,8331554,CSF/plasma (unbound) ratios,"The CSF/plasma (unbound) ratios of ramiprilat on day 7 were (mean +/- S.D.): 0.01 +/- 0.003 (2 h after dose), 0.18 +/- 0.05 (12 h after dose) and 0.32 +/- 0.11 (24 h after dose).",Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331554/),,0.32,267705,DB00178,Ramipril
,8331554,bioavailability,"Measurable concentrations of ramipril were recorded in plasma after oral dosing (bioavailability approximately 45%), whereas in CSF the prodrug concentration was below the minimal determinable levels in most cases.",Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331554/),%,45,267706,DB00178,Ramipril
,8331554,clearance,"Ramipril was rapidly cleared from the plasma, clearance being approximately 140 ml/min/kg and half-life about 0.5 h on day 7.",Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331554/),[ml] / [kg·min],140,267707,DB00178,Ramipril
,8331554,half-life,"Ramipril was rapidly cleared from the plasma, clearance being approximately 140 ml/min/kg and half-life about 0.5 h on day 7.",Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331554/),h,0.5,267708,DB00178,Ramipril
> or =,18638296,apparent terminal half-life (t((1/2)beta)),The apparent terminal half-life (t((1/2)beta)) was > or =20 h irrespective of the dose.,Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat in healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638296/),h,20,270947,DB00178,Ramipril
